Evolocumab for Lowering Cholesterol in Stroke Patients
Author Information
Author(s): Qiu Xiaohui, Liang Yeyuan, Wei Yunfei, Lu Mengru, Mei Yujia, Tang Shiting, Tang Jian, Liang Jinyu, Liang Junli
Primary Institution: The Second Affiliated Hospital of Guangxi Medical University
Hypothesis
Adding evolocumab to standard treatment will better reduce LDL-C levels in acute ischemic stroke patients.
Conclusion
Evolocumab significantly reduced LDL-C levels in early acute ischemic stroke patients and was well tolerated.
Supporting Evidence
- LDL-C levels decreased from 3.15 mmol/L to 0.85 mmol/L in the evolocumab group.
- 81.67% of patients in the evolocumab group achieved LDL-C <1.4 mmol/L.
- The study was conducted over 8 weeks with regular follow-ups.
- Adverse events were similar between the two groups.
- Mean LDL-C reduction was significantly greater in the evolocumab group compared to the control group.
Takeaway
This study shows that a new medicine called evolocumab can help lower bad cholesterol in people who have had a stroke, making them healthier.
Methodology
A randomized controlled trial with 120 acute ischemic stroke patients assigned to receive either evolocumab or standard care.
Potential Biases
Potential bias due to the unblinded design and single-center recruitment.
Limitations
Single-center study with a limited sample size and no blinding.
Participant Demographics
Mean age of participants was approximately 61 years, with a mix of genders and health conditions.
Statistical Information
P-Value
<0.001
Confidence Interval
−1.70 to −1.04
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website